Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 1, 2007, Pages 17-21

  Park, Keon Woo ^b   Ahn, Jin Seok ^a   Park, Young Suk ^a   Lee, Jeeyun ^a   Kang, Jung Hoon ^a   Park, Joon Oh ^a   Lim, Ho Yeong ^a   Im, Young Hyuck ^a   Kang, Won Ki ^a   Park, Keunchil ^a   Lee, Soon Il ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Dankook University   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Gastric cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DIARRHEA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; NEUTROPENIA; PALLIATIVE CARE; STOMACH NEOPLASMS; TAXOIDS; VOMITING;

EID: 33751262211     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0253-2     Document Type: Article

References (19)

1. Bae JM, Won YJ, Jung KW, Park JG (2002) Annual report of the Korea Central Cancer Registry Program 2000: based on registered data from 131 hospitals. Cancer Res 34:77
2. Pyrhonen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587
3. Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gasric cancer. Cancer 72:37
4. Schipper DL, Wagener DJ (1996) Chemotherapy of gastric cancer. Anticancer Drugs 7:137
5. Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163
6. Preusser P, Achterrath W, Wilke H et al (1998) Chemotherapy of gastric cancer. Cancer Treat Rev 15:257
7. Cutsem EV (2004) The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologists 9:9
8. Sulkes A, Smyth J, Sessa C et al (1994) Docetaxel (Taxotere®) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70:380
9. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32:248
10. Roth AD, Mailbach R, MArtinelli G et al (2000) Docetaxel (Taxotere)l-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301
11. Roth AD, Mailbach R, Falk S et al (2004) Docetaxel-cisplatin-5-FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-visplatin-5-FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 22:318s
12. Ajani J, Fodor M, Tjulandin S et al (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660
13. Moiseyenko V, Ajani J, Tjulandin S et al (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J Clin Oncol 23:308s
14. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207
15. Kettner E, Ridwelski K, Keilholtz U et al (2001) Docetaxel and cisplatin combination therapy for advanced gastric cancer: results of two phase II studies. Proc Am Soc Clin Oncol 20:163
16. Ridwelski K, Gebauer T, Fahlke J et al (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47
17. Georgoulias V, Androulakis N, Dimopoulos AM et al (1998) First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 9:331
18. Lee SH, Kang WK, Park J et al (2004) Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br J Cancer 91:18
19. Park SH, Kang WK, Lee HR et al (2004) Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol 27:477